Common cold

Jumptuit Health Unveils Geolocation Health Scenario Forecasting for Environmental Exposures, Viruses and Diseases

Retrieved on: 
Thursday, December 15, 2022
Water, Travel, Particulates, Nitrogen dioxide, Notification, COVID-19, Virus, Food, Air pollution, Atmosphere, Ecosystem, Environment, NO2, Public health, Infection, Common cold, Software as a service, Children's Environmental Exposure Research Study, HPA, AQI, Common, Sulfur dioxide, Health, SO2, Behavior, Death, Safety, RSV, Ultraviolet index, Climate change, Barometer, Agriculture, Vaccine, Risk management, Humidity, Pneumonia, Temperature, Altitude, Ozone, Tuberculosis

NEW YORK, Dec. 15, 2022 /PRNewswire/ -- Jumptuit Health http://www.jumptuit.co announced today the market availability of its Individualized Preventive Health Forecast Alerts and Notifications SaaS modules on January 16, 2023.

Key Points: 
  • Jumptuit Health reduces dangerous exposures to climate change induced extreme heat and cold events, increased frequency of wildfire pollution, and airborne and contact viruses.
  • Environmental Exposure Forecasts enable individuals to modify their behavior based on threshold levels that generate alerts, mitigating the unhealthy effects of climate change and pollution, viruses and toxins on an individual's health.
  • Jumptuit Health analyzes how an individual's health attributes may be affected by these forecasted exposures.
  • Jumptuit Health provides geolocation forecasts of environmental exposures, viruses and diseases in relation to an individual's health attributes and behaviors, empowering them to avoid, circumvent or bypass potentially unhealthy or dangerous scenarios.

Global Infectious Diseases Partnering Deal Trends, Players and Financials Analysis Report 2015-2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 25, 2022
Health, Infectious Diseases, Campylobacter jejuni, MRSA, SEC, Directory, Review, Yellow fever, Salmonella, Global Infectious Disease Epidemiology Network, Chapter Three, Chapter One, Respiratory syncytial virus, Orientation, Contract, RSV, Chapter Five, Research, Anthrax, FIV, Methicillin-resistant Staphylococcus aureus, Escherichia coli, Technology, Haemophilus influenzae, Common cold, HIV, Chapter Six, Foot, Chapter Two, Herpes simplex, Dengue fever, A-Z, Tetanus, Mycobacterium avium complex, Streptococcus, Clostridium difficile, Hepatitis A, Lyme disease, Chapter Four, Pseudomonas aeruginosa, African trypanosomiasis, Hyperlink, Helicobacter pylori, TB, Vaccine, Pharmaceutical industry, Haemophilus, West Nile virus, Infection, Tuberculosis, H1N1, Zika fever, Sepsis, Cytomegalovirus, Diphtheria, Malaria

The "Global Infectious Diseases Partnering 2015-2022: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Infectious Diseases Partnering 2015-2022: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
  • The Global Infectious Diseases Partnering 2015-2022 report provides comprehensive access to available deals and contract documents for over 2,900 infectious diseases deals.
  • The report takes readers through the comprehensive Infectious Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Infectious Diseases deals.
  • Chapter 6 provides a comprehensive directory of all Infectious Diseases partnering deals by specific Infectious Diseases target announced since 2015.

Xlear Files Amended Answer to the Government’s Lawsuit on COVID-19 Statements; Provides Still More Data In Support of Xlear’s Use as Additional Layer of Protection

Retrieved on: 
Monday, August 15, 2022
Public Policy, Government, Courts, Other Science, Research, Healthcare Reform, Science, Other Travel, Public Safety, Other Health, Travel, Pharmaceutical, Other Retail, Infectious Diseases, Other Consumer, Women, COVID-19, Seniors, Specialty, Clinical Trials, Men, Parenting, Alternative Medicine, Children, Family, Retail, Health, Consumer, Public Policy, Other Policy Issues, Vitamins, Supplements, Zinc, Death, NIH, CEO, Face, Analgesic, COVID, GSE, PMID, Pharmacology, Defendant, Research, Translation, Coronavirus, Privacy and the US government, Court, Federal government of the United States, COVID-19, Charles Degeorge, Infection, Nose, Federal Court of Canada, DOI, Federal court, Cristiane Rozeira, Decongestant, Common cold, Government, Common, Science, Severe acute respiratory syndrome coronavirus 2, Time, Disease, Pharmaceutical industry

Nate Jones, CEO of Xlear noted, The Government agrees, Xlear is a saline nasal solution.

Key Points: 
  • Nate Jones, CEO of Xlear noted, The Government agrees, Xlear is a saline nasal solution.
  • New in silico research determined that compounds of grapefruit seed extract (GSE) were effective inhibitors of the SARS-CoV-2 virus.
  • Most importantly, these experts concluded natural GSEwhich is a component of Xlearwas more effective than synthetic versions of the compound.
  • As part of its efforts to silence Xlear, the Government asked the Utah Federal Court to preclude Xlear from filing the Amended Answer.

Nasopharyngitis (Common Cold) Drugs in Development, 2022 Update - Featuring Adare Pharma Solutions, Charleston Labs, Eurofarma Labs, Pfizer, SaNOtize R&D Corp, and Tris Pharma Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, March 11, 2022
Health, Pharmaceutical, Molecule, Company, Mall of America, File, SEC, Target, Discovery, History, R, Research, Decision-making, Therapy, News, Pharmaceutical industry, Surveying, Petroleum jelly, Marketing, Common cold

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Key Points: 
  • The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
  • The Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Nasopharyngitis (Common Cold) and features dormant and discontinued projects.
  • Formulate corrective measures for pipeline projects by understanding Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Global Infectious Diseases Partnering Analysis Report 2014-2021: Deal Trends, Players and Financials for Over 2,600 Deals - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 11, 2022
Health, Infectious Diseases, Helicobacter pylori, Anthrax, Research, Technology, Herpes simplex, Mycobacterium avium complex, Tetanus, TB, Center for Global Infectious Disease Research, Dengue fever, Respiratory syncytial virus, RSV, Campylobacter jejuni, Streptococcus, Escherichia coli, Haemophilus influenzae, MRSA, Hepatitis A, Methicillin-resistant Staphylococcus aureus, Yellow fever, Infection, HIV, Salmonella, Clostridium difficile, FIV, Common cold, Contract, African trypanosomiasis, Foot, Hyperlink, Pseudomonas aeruginosa, A-Z, Lyme disease, Vaccine, Pharmaceutical industry, Aquaculture, Malaria, Diphtheria, West Nile virus, Cytomegalovirus, Sepsis, Tuberculosis, H1N1, Haemophilus, Zika fever

The "Global Infectious Diseases Partnering 2014-2021: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Infectious Diseases Partnering 2014-2021: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
  • The Global Infectious Diseases Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 2,600 infectious diseases deals.
  • The report takes readers through the comprehensive Infectious Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Infectious Diseases deals.
  • In addition, a comprehensive appendix is provided with each report of all Infectious Diseases partnering deals signed and announced since 2014.

AIM ImmunoTech Announces Phase 2a Human Challenge Trial to Test its Drug Ampligen as an Intranasal Antiviral Prophylactic Therapy

Retrieved on: 
Friday, July 9, 2021
Health sciences, Health, Medicine, Drug discovery, Rintatolimod, AIM ImmunoTech, Common cold, Rhinovirus, Antiviral drug, Therapy, Live attenuated influenza vaccine, Nasal administration

OCALA, Fla., July 09, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test the companys drug Ampligen as a potential intranasal antiviral therapy using a human Rhinovirus hRV (common cold virus) and Influenza.

Key Points: 
  • OCALA, Fla., July 09, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test the companys drug Ampligen as a potential intranasal antiviral therapy using a human Rhinovirus hRV (common cold virus) and Influenza.
  • In an HCT, subjects are intentionally exposed to particular diseases to test how the diseases will respond to potential therapeutics.
  • This Phase 2a study will come in the wake of AIMs recent announcement that all subjects have completed treatment in the companys Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as a potential intranasal therapy.
  • Open Orphan has a leading portfolio of eight human challenge study models for conditions such as RSV, flu, asthma and COPD.

Ohio Becomes 21st State to Adopt Age-18 Sales Law for Cough Medicine

Retrieved on: 
Thursday, July 1, 2021
Public policy, Government, General Health, Health, State, Local, Psychoactive drugs, Drugs, Antitussives, Morphinans, Cold medicine, Dextromethorphan, Common cold, CHPA

When used as directed, DXM is a safe and effective cough suppressant found in OTC cough and cold products.

Key Points: 
  • When used as directed, DXM is a safe and effective cough suppressant found in OTC cough and cold products.
  • CHPA thanks Governor DeWine for signing this important bill into law, as well as Representative Koehler for his tireless leadership on this issue, said Melville.
  • Smart public policy and education are both vitally important to combating teen OTC cough medicine abuse.
  • In 2012, California became the first state to prohibit sales of DXM-containing products to minors.

Sales of OTC Remedies for Colds & Coughs Climb as Face Mask Sales Decline

Retrieved on: 
Monday, June 21, 2021
Drugs, Medical specialties, Analgesics, Antipyretics, Clinical medicine, Tylenol, Common cold, Paracetamol

"With face masks coming off, sales of OTC remedies for coughs, colds and allergies on the rise."

Key Points: 
  • "With face masks coming off, sales of OTC remedies for coughs, colds and allergies on the rise."
  • This behavior has also been credited for cutting down on the number of people suffering from more commonly transmitted colds and coughs over the past year.
  • Meanwhile, sales of children's analgesics climbed 78 percent during that same timeframe, with Motrin up 96% and Tylenol up 76%.
  • Meanwhile, allergy sufferers who are back to spending more time outdoors have been buying more OTC remedies this year than they did last.

Elder Berry Adulteration Documented by New Botanical Adulterants Prevention Program Article

Retrieved on: 
Tuesday, March 23, 2021
Medical specialties, Clinical medicine, Infectious diseases, Medicine, Dietary supplement, BAPP, Common cold, Adulterant, Respiratory tract infection, Upper respiratory tract infection

Dietary supplements containing elder berry are widely used medicinally to treat symptoms of upper respiratory infections associated with colds and flus.

Key Points: 
  • Dietary supplements containing elder berry are widely used medicinally to treat symptoms of upper respiratory infections associated with colds and flus.
  • The elder berry adulteration article is the 64th peer-reviewed publication by BAPP, all of which are available for free access on the BAPP site .
  • To date, BAPP has published 64 peer-reviewed documents, including Botanical Adulterants Prevention Bulletins, Laboratory Guidance Documents, Botanical Adulterants Monitor e-newsletters, and others.
  • As with all of the programs publications, this review of elder berry adulteration is freely accessible on the programs website (registration required).

Global Respiratory Infection Diagnostic Markets Report 2021-2025 with COVID-19 Impact, Forecasting/Analysis & Executive and Consultant Guides

Retrieved on: 
Wednesday, January 27, 2021
Medical specialties, Clinical medicine, Medicine, Respiratory diseases, Coronavirus disease, Occupational safety and health, Zoonoses, Common cold, Respiratory tract infection

DUBLIN, Jan. 27, 2021 /PRNewswire/ -- The "Respiratory Infection Diagnostic Markets by Technology, Plex, Place and by Region with COVID-19 Impact & Forecasting/Analysis, and Executive and Consultant Guides 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 27, 2021 /PRNewswire/ -- The "Respiratory Infection Diagnostic Markets by Technology, Plex, Place and by Region with COVID-19 Impact & Forecasting/Analysis, and Executive and Consultant Guides 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • The Multiplex factor is creating market confusion while lowering costs and improving care but important factors are holding back progress.
  • COVID-19 has broken open the market for point of care testing of respiratory infections.
  • The widespread nature of respiratory infections, (young people can get 8 colds a year) means that potential market sizes are enormous.